Latest:
What’s Coming Next in Relapsed/Refractory Multiple Myeloma
Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Authors
Megan Hollasch
Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication
Latest:
Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer
Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.
Genmab and AbbVie Sponsored Content; OncLive Article with Tahi Ahmadi and Asud Khaliq
Latest:
Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.
Thor R. Halfdanarson, MD
Latest:
Interpreting the Clinical Efficacy of Cabozantinib in NETs
Panelists discuss the CABINET trial’s findings that cabozantinib significantly improved progression-free survival in both pancreatic and extrapancreatic neuroendocrine tumors, highlighting its efficacy in a heavily pretreated, real-world population and noting the trial’s inclusive design, crossover protocol, and implications for broader clinical use.
Indiana University School of Medicine
Latest:
$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural Indiana
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.
Angela Jain, MD
Angela Jain, MD, is an associate professor, Department of Hematology/Oncology; interim chief of the Division of Breast Medical Oncology; and chief of the Division of Gynecologic Medical Oncology, of Fox Chase Cancer Center.
Latest:
Dr Jain on Existing Challenges Within the TNBC Treatment Paradigm
Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.